Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreem

Angelini Pharma secures exclusive global license rights to future identified drug targets
Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience